Published in Nat Med on June 06, 2004
O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science (2010) 2.98
Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science (2012) 2.22
Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol (2005) 2.17
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet (2012) 1.93
Developmental and pathogenic mechanisms of basement membrane assembly. Curr Pharm Des (2009) 1.80
Duchenne muscular dystrophy and dystrophin: pathogenesis and opportunities for treatment. EMBO Rep (2004) 1.66
SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science (2013) 1.57
Enhanced laminin binding by alpha-dystroglycan after enzymatic deglycosylation. Biochem J (2005) 1.56
Muscular dystrophies due to glycosylation defects. Neurotherapeutics (2008) 1.51
Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome. Hum Genet (2007) 1.51
Basal lamina strengthens cell membrane integrity via the laminin G domain-binding motif of alpha-dystroglycan. Proc Natl Acad Sci U S A (2009) 1.47
Identification of mutations in TMEM5 and ISPD as a cause of severe cobblestone lissencephaly. Am J Hum Genet (2012) 1.44
Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy. Nature (2011) 1.41
Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci U S A (2009) 1.32
Like-acetylglucosaminyltransferase (LARGE)-dependent modification of dystroglycan at Thr-317/319 is required for laminin binding and arenavirus infection. Proc Natl Acad Sci U S A (2011) 1.32
Glycosylation diseases: quo vadis? Biochim Biophys Acta (2008) 1.30
The o-mannosylation pathway: glycosyltransferases and proteins implicated in congenital muscular dystrophy. J Biol Chem (2013) 1.28
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
Old World and clade C New World arenaviruses mimic the molecular mechanism of receptor recognition used by alpha-dystroglycan's host-derived ligands. J Virol (2007) 1.24
Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry. J Virol (2011) 1.23
Brain and eye malformations resembling Walker-Warburg syndrome are recapitulated in mice by dystroglycan deletion in the epiblast. J Neurosci (2008) 1.22
Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J Neurosci (2010) 1.20
Old World arenavirus infection interferes with the expression of functional alpha-dystroglycan in the host cell. Mol Biol Cell (2007) 1.12
Residual laminin-binding activity and enhanced dystroglycan glycosylation by LARGE in novel model mice to dystroglycanopathy. Hum Mol Genet (2008) 1.10
Mechanisms of disease: congenital muscular dystrophies-glycosylation takes center stage. Nat Clin Pract Neurol (2006) 1.10
Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One (2012) 1.10
The congenital muscular dystrophies: recent advances and molecular insights. Pediatr Dev Pathol (2006) 1.09
O Mannosylation of alpha-dystroglycan is essential for lymphocytic choriomeningitis virus receptor function. J Virol (2005) 1.06
Congenital muscular dystrophies involving the O-mannose pathway. Curr Mol Med (2007) 1.06
Matriglycan: a novel polysaccharide that links dystroglycan to the basement membrane. Glycobiology (2015) 1.06
Dissecting the molecular basis of the role of the O-mannosylation pathway in disease: α-dystroglycan and forms of muscular dystrophy. Chembiochem (2013) 1.04
LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy. Nature (2013) 1.04
Dystroglycan matrix receptor function in cardiac myocytes is important for limiting activity-induced myocardial damage. Circ Res (2009) 1.03
Mutational and functional analysis of Large in a novel CHO glycosylation mutant. Glycobiology (2009) 1.02
The dystroglycanopathies: the new disorders of O-linked glycosylation. Semin Pediatr Neurol (2005) 0.99
Golgi glycosylation and human inherited diseases. Cold Spring Harb Perspect Biol (2011) 0.99
The glucuronyltransferase B4GAT1 is required for initiation of LARGE-mediated α-dystroglycan functional glycosylation. Elife (2014) 0.98
Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase. Glycobiology (2011) 0.98
Dystroglycan glycosylation and muscular dystrophy. Glycoconj J (2008) 0.97
Transgenic overexpression of LARGE induces α-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS One (2010) 0.95
The intracellular Ca²⁺ channel MCOLN1 is required for sarcolemma repair to prevent muscular dystrophy. Nat Med (2014) 0.94
Post-translational maturation of dystroglycan is necessary for pikachurin binding and ribbon synaptic localization. J Biol Chem (2010) 0.93
Mammalian O-mannosylation: unsolved questions of structure/function. Curr Opin Struct Biol (2011) 0.93
Mammalian O-mannosylation pathway: glycan structures, enzymes, and protein substrates. Biochemistry (2014) 0.92
O-Mannosylation and human disease. Cell Mol Life Sci (2012) 0.91
Protein O-mannosylation in animal development and physiology: from human disorders to Drosophila phenotypes. Semin Cell Dev Biol (2010) 0.91
Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan. J Biol Chem (2012) 0.91
Xylosyl- and glucuronyltransferase functions of LARGE in α-dystroglycan modification are conserved in LARGE2. Glycobiology (2012) 0.91
Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on alpha-dystroglycan. PLoS One (2011) 0.91
LARGE expression augments the glycosylation of glycoproteins in addition to α-dystroglycan conferring laminin binding. PLoS One (2011) 0.90
Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. J Neurol (2009) 0.89
Pikachurin interaction with dystroglycan is diminished by defective O-mannosyl glycosylation in congenital muscular dystrophy models and rescued by LARGE overexpression. Neurosci Lett (2010) 0.88
Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses. Proc Natl Acad Sci U S A (2014) 0.87
Brain-specific expression of N-acetylglucosaminyltransferase IX (GnT-IX) is regulated by epigenetic histone modifications. J Biol Chem (2011) 0.87
Soleus muscle in glycosylation-deficient muscular dystrophy is protected from contraction-induced injury. Am J Physiol Cell Physiol (2010) 0.87
The functional O-mannose glycan on α-dystroglycan contains a phospho-ribitol primed for matriglycan addition. Elife (2016) 0.87
Binding of Lassa virus perturbs extracellular matrix-induced signal transduction via dystroglycan. Cell Microbiol (2012) 0.86
Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer. J Biol Chem (2012) 0.86
New dystrophin/dystroglycan interactors control neuron behavior in Drosophila eye. BMC Neurosci (2011) 0.86
Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function. Hum Mol Genet (2011) 0.86
Aberrant development of neuromuscular junctions in glycosylation-defective Large(myd) mice. Neuromuscul Disord (2009) 0.85
Fer kinase regulates cell migration through α-dystroglycan glycosylation. Mol Biol Cell (2012) 0.85
Glycosylation eases muscular dystrophy. Nat Med (2004) 0.84
Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum Gene Ther (2013) 0.84
Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression. Sci Rep (2015) 0.83
Human natural killer-1 sulfotransferase (HNK-1ST)-induced sulfate transfer regulates laminin-binding glycans on α-dystroglycan. J Biol Chem (2012) 0.83
Adeno-associated virus-mediated overexpression of LARGE rescues α-dystroglycan function in dystrophic mice with mutations in the fukutin-related protein. Hum Gene Ther Methods (2014) 0.82
Therapies and therapeutic approaches in Congenital Disorders of Glycosylation. Glycoconj J (2012) 0.80
Clinical, pathologic, and mutational spectrum of dystroglycanopathy caused by LARGE mutations. J Neuropathol Exp Neurol (2014) 0.80
High throughput screening for compounds that alter muscle cell glycosylation identifies new role for N-glycans in regulating sarcolemmal protein abundance and laminin binding. J Biol Chem (2012) 0.80
Muscle-specific expression of LARGE restores neuromuscular transmission deficits in dystrophic LARGE(myd) mice. Hum Mol Genet (2012) 0.79
Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review). Mol Med Rep (2014) 0.78
Protein O-mannosylation in metazoan organisms. Curr Protoc Protein Sci (2014) 0.78
Endogenous glucuronyltransferase activity of LARGE or LARGE2 required for functional modification of α-dystroglycan in cells and tissues. J Biol Chem (2014) 0.78
A comparative study of N-glycolylneuraminic acid (Neu5Gc) and cytotoxic T cell (CT) carbohydrate expression in normal and dystrophin-deficient dog and human skeletal muscle. PLoS One (2014) 0.78
A Method to Produce and Purify Full-Length Recombinant Alpha Dystroglycan: Analysis of N- and O-Linked Monosaccharide Composition in CHO Cells with or without LARGE Overexpression. PLoS Curr (2013) 0.78
Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies. Neurotherapeutics (2008) 0.77
Congenital protein hypoglycosylation diseases. Appl Clin Genet (2012) 0.75
Genetic Engineering of Dystroglycan in Animal Models of Muscular Dystrophy. Biomed Res Int (2015) 0.75
Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex. Anat Rec (Hoboken) (2014) 0.75
Transgenic Rescue of the LARGEmyd Mouse: A LARGE Therapeutic Window? PLoS One (2016) 0.75
Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy. Matrix Biol (2013) 0.75
Report on the 3rd Ottawa International Conference on Neuromuscular Biology, Disease and Therapy - September 24-26, 2015, Ottawa, Canada. J Neuromuscul Dis (2016) 0.75
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature (2003) 6.50
The draft genome of the transgenic tropical fruit tree papaya (Carica papaya Linnaeus). Nature (2008) 5.54
Phenotypically concordant and discordant monozygotic twins display different DNA copy-number-variation profiles. Am J Hum Genet (2008) 5.53
Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature (2002) 5.21
Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med (2002) 5.07
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature (2010) 4.12
Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature (2002) 3.96
Dystroglycan: from biosynthesis to pathogenesis of human disease. J Cell Sci (2006) 3.92
Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A (2007) 3.72
Noncanonical TGFβ signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science (2011) 3.49
Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science (2003) 3.21
Dystrophic heart failure blocked by membrane sealant poloxamer. Nature (2005) 3.16
Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Curr Opin Genet Dev (2002) 3.15
Auxiliary subunits: essential components of the voltage-gated calcium channel complex. Curr Opin Neurobiol (2003) 3.10
Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. J Clin Invest (2009) 3.05
Structural analysis of the voltage-dependent calcium channel beta subunit functional core and its complex with the alpha 1 interaction domain. Neuron (2004) 3.05
O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science (2010) 2.98
Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature (2008) 2.87
PGC-1alpha regulates the neuromuscular junction program and ameliorates Duchenne muscular dystrophy. Genes Dev (2007) 2.79
Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control. J Biol Chem (2004) 2.72
CaMKII determines mitochondrial stress responses in heart. Nature (2012) 2.63
Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem (2003) 2.56
Dysferlin and the plasma membrane repair in muscular dystrophy. Trends Cell Biol (2004) 2.41
Are voltage-dependent ion channels involved in the endothelial cell control of vasomotor tone? Am J Physiol Heart Circ Physiol (2007) 2.41
Pikachurin, a dystroglycan ligand, is essential for photoreceptor ribbon synapse formation. Nat Neurosci (2008) 2.35
New World arenavirus clade C, but not clade A and B viruses, utilizes alpha-dystroglycan as its major receptor. J Virol (2002) 2.35
Molecular recognition by LARGE is essential for expression of functional dystroglycan. Cell (2004) 2.33
Somatic mosaicism for copy number variation in differentiated human tissues. Hum Mutat (2008) 2.30
Gene amplification confers glyphosate resistance in Amaranthus palmeri. Proc Natl Acad Sci U S A (2009) 2.23
Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science (2012) 2.22
Posttranslational modification of alpha-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J Virol (2005) 2.17
Identification and characterization of a functional mitochondrial angiotensin system. Proc Natl Acad Sci U S A (2011) 2.16
Age-related somatic structural changes in the nuclear genome of human blood cells. Am J Hum Genet (2012) 2.15
Retracted VMA21 deficiency causes an autophagic myopathy by compromising V-ATPase activity and lysosomal acidification. Cell (2009) 2.11
The genetics revolution and primary care pediatrics. JAMA (2008) 2.09
Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. Science (2003) 2.05
The unfolded protein response mediates adaptation to exercise in skeletal muscle through a PGC-1α/ATF6α complex. Cell Metab (2011) 2.02
Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell (2002) 2.01
RIM1 confers sustained activity and neurotransmitter vesicle anchoring to presynaptic Ca2+ channels. Nat Neurosci (2007) 1.95
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
ISPD loss-of-function mutations disrupt dystroglycan O-mannosylation and cause Walker-Warburg syndrome. Nat Genet (2012) 1.93
Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. J Clin Invest (2007) 1.88
Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med (2011) 1.87
Dysferlin and muscle membrane repair. Curr Opin Cell Biol (2007) 1.82
Lateral transmission of force is impaired in skeletal muscles of dystrophic mice and very old rats. J Physiol (2011) 1.80
Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron (2003) 1.80
Regulation of muscle mass by follistatin and activins. Mol Endocrinol (2010) 1.79
Exon array CGH: detection of copy-number changes at the resolution of individual exons in the human genome. Am J Hum Genet (2005) 1.78
A critical role for muscle ring finger-1 in acute lung injury-associated skeletal muscle wasting. Am J Respir Crit Care Med (2012) 1.74
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Retracted A Gne knockout mouse expressing human V572L mutation develops features similar to distal myopathy with rimmed vacuoles or hereditary inclusion body myopathy. Hum Mol Genet (2006) 1.70
A full-coverage, high-resolution human chromosome 22 genomic microarray for clinical and research applications. Hum Mol Genet (2002) 1.69
A dystroglycan mutation associated with limb-girdle muscular dystrophy. N Engl J Med (2011) 1.67
Identification of a functional peroxisome proliferator-activated receptor response element in the rat catalase promoter. Mol Endocrinol (2002) 1.67
Chromatin immunoprecipitation cloning reveals rapid evolutionary patterns of centromeric DNA in Oryza species. Proc Natl Acad Sci U S A (2005) 1.64
Lysosomal myopathies: an excessive build-up in autophagosomes is too much to handle. Neuromuscul Disord (2008) 1.61
Walker-Warburg syndrome. Orphanet J Rare Dis (2006) 1.59
Limb-girdle muscular dystrophy in the United States. J Neuropathol Exp Neurol (2006) 1.59
Insulin-like growth factor 2 (IGF-2) potentiates BMP-9-induced osteogenic differentiation and bone formation. J Bone Miner Res (2010) 1.58
Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat Med (2009) 1.57
SGK196 is a glycosylation-specific O-mannose kinase required for dystroglycan function. Science (2013) 1.57
Rapid and accurate diagnosis of facioscapulohumeral muscular dystrophy. Neuromuscul Disord (2006) 1.56
Genomic microarrays in the spotlight. Trends Genet (2004) 1.55
Unilateral carrageenan injection into muscle or joint induces chronic bilateral hyperalgesia in rats. Pain (2003) 1.55
Repeatless and repeat-based centromeres in potato: implications for centromere evolution. Plant Cell (2012) 1.54
Transcriptional upregulation of Cav3.2 mediates epileptogenesis in the pilocarpine model of epilepsy. J Neurosci (2008) 1.54
Altered thymidine metabolism due to defects of thymidine phosphorylase. J Biol Chem (2001) 1.52
Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem (2004) 1.52
Hibernating squirrel muscle activates the endurance exercise pathway despite prolonged immobilization. Exp Neurol (2013) 1.52
Mutations in GDP-mannose pyrophosphorylase B cause congenital and limb-girdle muscular dystrophies associated with hypoglycosylation of α-dystroglycan. Am J Hum Genet (2013) 1.50
Genetic evaluation of the pediatric patient with hypotonia: perspective from a hypotonia specialty clinic and review of the literature. Dev Med Child Neurol (2011) 1.49
Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring. J Cell Sci (2006) 1.49
C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol (2007) 1.47
Point mutation in the glycoprotein of lymphocytic choriomeningitis virus is necessary for receptor binding, dendritic cell infection, and long-term persistence. Proc Natl Acad Sci U S A (2011) 1.47